This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugiyama, Y. Articles by Bankert, R. B. Search for Related Content PubMed PubMed Citation Articles by Sugiyama, Y. Articles by Bankert, R. B.

Selective Growth Inhibition of Human Lung Cancer Cell Lines Bearing a Surface Glycoprotein gp160 by ¹²⁵I-labeled Anti-gp160 Monoclonal Antibody¹

Departments of Molecular Immunology [Y. S., F-A. C., R. B. B.] and Thoracic Surgery [H. T.], Roswell Park Memorial Institute,^,3 Buffalo, New York 14263

Monoclonal antibody 5E8 which is specific for a M_r 160,000 glycoprotein (gp160) on the surface of human lung cancer was radiolabeled with ¹²⁵I. Radiolabeled 5E8 antibody is shown here to suppress the growth of gp160 positive human lung tumor cell lines in a dose-dependent fashion, but this same radiolabeled antibody does not alter the growth of gp160 negative lung tumor cell lines. Neither the unlabeled 5E8 nor a control radiolabeled monoclonal antibody has any effect upon the growth of gp160 positive tumors. The specificity of radiolabeled antibody mediated tumor killing is further demonstrated by the ability of unlabeled 5E8 to inhibit tumor killing by ¹²⁵I-5E8. The efficiency with which the labeled tumor specific antibody suppressed tumor colony formation is enhanced by increasing the molar ratio of ¹²⁵I to 5E8. This ratio could be increased to a level of two without affecting the capacity of the antibody to bind to the cell surface antigen. An attempt to increase the efficiency of tumor killing by the addition of a second antibody subsequent to incubation with ¹²⁵I-5E8 was unsuccessful. These results indicate that ¹²⁵I is a viable isotope and gp160 represents an appropriate target for radioimmunotherapy of human lung cancer.

¹ This work was supported in part by USPHS grants CA33462, CA22786, and CA25253.

² To whom requests for reprints should be addressed, at Molecular Immunology, Roswell Park Memorial Institute, 666 Elm Street, Buffalo, NY 14263.

³ A unit of New York State Department of Health.

Received 10/ 7/87. Revised 1/ 4/88. Accepted 2/16/88.

This article has been cited by other articles:

				R. B. Michel, M. E. Castillo, P. M. Andrews, and M. J. Mattes In vitro Toxicity of A-431 Carcinoma Cells with Antibodies to Epidermal Growth Factor Receptor and Epithelial Glycoprotein-1 Conjugated to Radionuclides Emitting Low-Energy Electrons Clin. Cancer Res., September 1, 2004; 10(17): 5957 - 5966. [Abstract] [Full Text] [PDF]